ASTELLA'S Pharma Australia has gained approval for Veoza to treat moderate-to-severe vasomotor symptoms of menopause, such as hot flushes and night sweats.
Veoza distinguishes itself as a once-daily oral pill and is a selective neurokinin 3 receptor antagonist, which moderates the brain's temperature regulation and helps to alleviate symptoms.
The approval stems from the results of the SKYLIGHT 1 and SKYLIGHT 2 Phase 3 studies, showcasing Veoza's efficacy in significantly reducing both the frequency and severity of menopausal symptoms in post-menopausal women.
Within the first four weeks, there was a reduction in symptoms, a trend that continued and improved through the 12 weeks of treatment for participants.
Prof Rodney Baber, from the Royal North Shore Hospital in Sydney, underscored the significance of this development, stating, "approval of Veoza means we can now offer a non-hormonal option that can reduce the frequency and severity of hot flushes and night sweats within one week of starting treatment for some women".
This comment highlights the drug's potential to improve the quality of life for sufferers of menopausal symptoms.
Veoza's introduction into the Australian market follows its approval in other major regions like the United States, the United Kingdom, and by the European Commission.
The above article was sent to subscribers in Pharmacy Daily's issue from 05 Apr 24
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 05 Apr 24
